Estimating the Economic Burden of Premature Mortality Caused by Cancer in Iran: 2006-2010

  • Karami-Matin, Behzad (Research Center for Environmental Determinants of Health, Kermanshah University of Medical Sciences) ;
  • Najafi, Farid (Research Center for Environmental Determinants of Health, Kermanshah University of Medical Sciences) ;
  • Rezaei, Satar (Research Center for Environmental Determinants of Health, Kermanshah University of Medical Sciences) ;
  • Khosravi, Ardashir (Ministry of Health and Medical Education) ;
  • Soofi, Moslem (Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences)
  • Published : 2016.06.01


Background: Cancer is currently one of the main public health problems all over the world and its economic burden is substantial both for health systems and for society as a whole. To inform priorities for cancer control, we here estimated years of potential life lost (YPLL) and productivity losses due to cancer-related premature mortality in Iran from 2006 to 2010. Materials and Methods: The number of cancer deaths by sex and age groups for top ten leading cancers in Iran were obtained from the Ministry of Health and Medical Education. To estimate the YPLL and the cost of productivity loss due to cancer-related premature mortality, the life expectancy method and the human capital approach were used, respectively. Results: There were 138,228 cancer-related deaths in Iran (without Tehran province) of which 76 % (106,954) were attributable to the top 10 ranked cancers. Some 63 % of total cancer-related deaths were of males. The top 10 ranked cancers resulted in 106,766,942 YPLL in total, 64,171,529 (60 %) in males and 42,595,412 (40%) in females. The estimated YPPLL due to top 10 ranked cancers was 58,581,737 during the period studied of which 32,214,524 (54%) was accounted for in males. The total cost of lost productivity caused by premature deaths because of top 10 cancers was 1.68 billion dollars (US$) from 2006 to 2010, ranging from 251 million dollars in 2006 to 283 million dollars in 2010. Conclusions: This study showed that the economic burden of premature mortality attributable to cancer is significant for Iranian society. The findings provide useful information about the economic impact of cancer for health system policy/decision makers and should facilitate planning of preventive intervention and effective resource allocation.


  1. Akbarzadehbaghban A, Esmaeili M, Kimiafar K (2009). Medical information management and assessment of direct costs of treatment of lung cancer. Health Information Manage, 5, 15-21.
  2. Bazyar M, Pourreza A, Harirchi I, et al (2012). Medical and non-medical direct costs of cancers in patients hospitalized in Imam Khomeini cancer institution-2010. Hospital, 11, 39-50.
  3. Bradley CJ, YabroffKR, DahmanB, et al (2008). Productivity costs of cancer mortality in the United States: 2000?2020. J Natl Cancer Inst, 100, 1763-70.
  4. Daroudi RA, Akbari SariA, Nahvijou A, et al (2015). The economic burden of breast cancer in Iran. Iran J Public Health, 44, 1225.
  5. Doran CM , Ling R, Byrnes J, et al (2015). Estimating the economic costs of skin cancer in New South Wales, Australia. BMC public health , 1, 952.
  6. Forouzanfar MH, Sepanlou SG, Shahraz S, et al (2014). Evaluating causes of death and morbidity in Iran, global burden of diseases, injuries, and risk factors study 2010. Arch Iran Med, 17, 304-320.
  7. Hanly PA, Sharp L (2014). The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden. BMC Cancer, 14, 224
  8. Insinga RP (2006). Annual productivity costs due to cervical cancer mortality in the United States. Womens Health Issues, 16, 236-42.
  9. Jemal A, F. Bray, MM. Center, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  10. Jemal A, Center MM, DeSantis C, et al (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19, 1893-907.
  11. Jonsson B, Wilking N (2007). The burden and cost of cancer. Ann Oncol, 18, 8-22.
  12. Abachizadeh K, Mohagheghi MA, Mosavi-Jarrahi A (2011). Setting research priorities to reduce burden of cancer in Iran: an institutional experience. Asian Pac J Cancer Prev, 12, 2365-70.
  13. Khorasani S, Rezaei S, Rashidian H, et al (2014). Years of potential life lost and productivity costs due to premature cancer-related mortality in Iran. Asian Pac JCancer Prev, 16, 1845-50.
  14. Kim JL, Cho KH, Park EC, et al (2013). A single measure of cancer burden combining incidence with mortality rates for worldwide application. Asian Pac J Cancer Prev, 15, 433-9.
  15. Menzin J, Marton JP, Menzin JA, et al (2012). Lost productivity due to premature mortality in developed and emerging countries: an application to smoking cessation. BMC Med Res Methodol, 12, 87.
  16. Naghavi M, Abolhassani F, PourmalekF, et al (2009). The burden of disease and injury in Iran 2003. Popul Health Metr, 7, 9-15.
  17. Ortiz-Ortiz KJ, Perez-Irizarry J, Marin-CentenoH, et al (2010). Productivity loss in Puerto Rico’s labor market due to cancer mortality. P R Health Sci J, 29, 241-9.
  18. LozanoR, NaghaviM, Foreman K, et al (2013). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380, 2095-2128.
  19. Rashidian H, Davoudi R, Ghiasvand R (2013). Prevalence and Incidence of premenopausal and postmenopausal breast cancer in Iran in 2010. Basic Clinical Cancer Res, 5, 2-10.
  20. Rezaei S, Akbari SariA, ArabM, et al (2015). Estimating economic burden of cancer deaths attributable to smoking in Iran in 2012. J Res Health Sci, 15, 228-33.
  21. Song X, Quek RG, Gandra SR, et al (2015). Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures. BMC Health Serv Res, 1, 254.
  22. Taghavi A, Fazeli Z, Vahedi M (2012). Increased trend of breast cancer mortality in Iran. Asian Pac J Cancer Prev, 13, 367-70.
  23. Torre LA, Bray F, Siegel RL, et al (2015). Global cancer statistics, 2012. CA Cancer J Clin, 65, 87-108.

Cited by

  1. Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention vol.63, pp.7, 2018,